Overview
The company is developing Launch-iT, a novel platform to create virus-targeted immunotherapies that address virus-driven cancers and other diseases. Their approach targets viral infections before they cause cancer, opening a new therapeutic space alongside prevention and treatment. The company focuses on conditions like HPV-driven cancer.
Key people
In the news
- This week, 𝗔𝘀𝘁𝗿𝗶𝘃𝗮𝘅 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 will be attending International Papillomavirus Society conference 2026 in Athens, where experts from across the world come together to advance science, share knowledge, and accelerate progress against HPV-related diseases and explore our 𝗟𝗮𝘂𝗻𝗰𝗵-𝗶𝗧, 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 𝘃𝗶𝗿𝗮𝗹-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗶𝘀𝗲𝗮𝘀𝗲. Brenda De Keersmaecker 𝗮𝗻𝗱 Laure Torfs are keen on connecting with the HPV community. #IPVS2026 #HPV #Immunotherapy #interceptcancer
- Dutch only: a great interview with Astrivax Therapeutics CEO Hanne Callewaert. A wide ranging discussion on vaccines, innovation and the ecosystem of drug development in general.
- Belgium has everything it takes to turn science into innovation. We have an incredibly strong lifesciences ecosystem, but we cannot take that strength for granted! If we want to build the innovations of tomorrow here, we need the courage to fund them today, when they are still early, ambitious and inherently risky. I shared some of my thoughts in this week’s Trends Talk. #pointofview #innovation #earlystage # Astrivax Therapeutics
- This 𝗔𝘀𝘁𝗿𝗶𝘃𝗮𝘅 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗧𝗲𝗮𝗺 will be at the 𝗪𝗼𝗿𝗹𝗱 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 Europe in Amsterdam next week, joining the global vaccine community to exchange ideas, explore collaborations, and discuss the latest advances in vaccine development. Are you attending as well? 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 to schedule a meeting with our team. We're always eager to connect with fellow innovators, potential partners, and experts working to shape the future of vaccines. 𝗦𝗲𝗲 𝘆𝗼𝘂 𝗶𝗻 𝗔𝗺𝘀𝘁𝗲𝗿𝗱𝗮𝗺! #WVC
- Astrivax Therapeutics is heading to the ISV Annual Congress 2026 in Antwerp (12–14 October)! We’re excited to present the first clinical results of our Launch-iT technology ISV! Lidia Oostvogels, Medical Consultant for Astrivax Therapeutics, will present on T𝘂𝗲𝘀𝗱𝗮𝘆 𝟭𝟯 𝗢𝗰𝘁𝗼𝗯𝗲𝗿, 𝟭𝟬:𝟭𝟱 𝗱𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗹𝗲𝗻𝗮𝗿𝘆 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗼𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆. Title of the talk: "Safety, Reactogenicity and Immunogenicity of a Launch-iT Rabies Vaccine: A Randomized, Double-Blind, Placebo-Controlled,
- Women’s Health is high on the agenda in Europe. This week I attended “From Challenges to Action: Scaling Women’s Health Innovation in Europe” at the European Parliament, organized by Eva Kopacz, Vice President of the European Parliament, European Innovation Council and SMEs Executive Agency (EISMEA). Scientists, entrepreneurs, innovators, physicians, investors and policymakers around the table. Different perspectives, but one very clear ask: 📢 Make it actionable. Over the last years, we have spent enough time identifying the
- Last week, Maria Fonseca joined #BostonBiotechWeek and #RESI in Boston on behalf of Obulytix, connecting with investors, biotech entrepreneurs, researchers, and industry leaders from across the life sciences ecosystem. A particular highlight was sharing the experience with the Belgian biotech delegation and exchanging perspectives on the challenges and opportunities of translating innovation from bench to patient in our local ecosystem. At RESI, organized by Life Science Nation, we gained valuable insights into US and
- A week ago, Friday night ... Good music. Good friends. Local festival. And then… one badly twisted ankle. My immediate thought: “I’m flying to the US in 36 hours. This cannot be happening.” Well, it was. Sunday morning, I boarded the plane, and spent the past week navigating the US and all my meetings on two crutches and more wheelchairs than I care to count. What made it possible? People. Airport assistance in Brussels, Munich, Boston and New York. The Belgian delegation in Boston carrying my luggage, backpack, coffee and food and
Something wrong or missing? Send an update. Fixed within 24 hours.